Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Hedge Funds-News

Myokardia Inc (MYOK): Cormorant Asset Management Raises Its Stake

Published on October 14, 2016 at 9:22 am by Insider Monkey Staff in Hedge Funds, News

Page 1 of 8

A recent 13G filing with the Securities and Exchange Commission revealed that Bihua Chen‘s Cormorant Asset Management has boosted its stake in Myokardia Inc (NASDAQ:MYOK) to 1.61 million shares, which represent 5.12% of the float. Previously, Cormorant Asset Management’s stake in the company consisted of 758,290 shares, as per its 13F filing for the reporting period of June 30.

Myokardia Inc (NASDAQ:MYOK) is a clinical-stage biopharmaceutical company that works on producing therapeutics for treating a group of rare heart disorders. Over the past 12 months, the company’s stock has gained 51.28%. For the second quarter of 2016, Myokardia disclosed a loss per share of $0.37 and revenue of $3.5 million, compared to a loss per share of $2.78 and the same revenue for the corresponding period of 2015. Recently, Wedbush reiterated its ‘Outperform’ rating on Myokardia’s stock but lowered its price target on it to $22 from $24.

bogdanhoda/Shutterstock.com

bogdanhoda/Shutterstock.com

Six of the smart money managers contained in our database reported holding long positions in Myokardia Inc (NASDAQ:MYOK) as of the end of June, down by one from the end of March. Among the bullish investors were Christopher Medlock James’ Partner Fund Management, which held a position valued at $10.40 million, Joseph Edelman’s Perceptive Advisors, with a position worth $6.24 million, James E. Flynn’s Deerfield Management, and Richard Driehaus’ Driehaus Capital.

Follow Myokardia Inc. (NASDAQ:MYOK)

Follow Myokardia Inc. (NASDAQ:MYOK)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Cormorant Global Healthcare Master Fund	0	1,339,426	0	1,339,426	1,339,426	4.27%
Cormorant Global Healthcare GP	0	1,339,426	0	1,339,426	1,339,426	4.27%
Cormorant Asset Management	0	1,605,790	0	1,605,790	1,605,790	5.12%
Bihua Chen	0	1,605,790	0	1,605,790	1,605,790	5.12%

Follow Bihua Chen's Cormorant Asset Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 8 – SEC Filing

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	SCHEDULE 13G
	Under the Securities Exchange Act of 1934
	(Amendment No. ___)*

	Myokardia, Inc.
	(Name of Issuer)

	Common Stock, par value $0.0001 per share
	(Title of Class of Securities)

	62857M105
	(CUSIP Number)

	September 28, 2016
	(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[x] Rule 13d-1(c)

[ ] Rule 13d-1(d)

___________________________________

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8

Bihua Chen NASDAQ:MYOK SEC 13G Filing Myokardia Inc (MYOK)Cormorant Asset Management Show more...Show less